Jonathan Myers, MD
Ophthalmology · Philadelphia, PANPI 1023013190
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $279,407 of the $358,632 with a category attached, or 77.9%. Glaukos Corporation accounts for 81.1% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2020 at $204,974 and has fallen 96.4% since, to $7,306 in 2025. Among ophthalmology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 113 payments — averaging $3173.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$291K
- AbbVie$39K
- Aerie Pharmaceuticals, Inc.$28K
- Alcon$114
- NEW World Medical,inc.$56
- Thea Pharma Inc.$22
- plus $3 from 1 others
Across 122 payments — averaging $2471.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$170K
- Glaukos Corporation$131K
- Sight Sciences, Inc.$500
What the payments were for
- Consulting fees$279,40778%
- Speaking & faculty fees$48,90014%
- Travel & lodging$27,6508%
- Food & beverage$2,6311%
- Gifts$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 31 | $290,925 |
| AbbVie(2 entities) | 51 | $39,076 |
| Aerie Pharmaceuticals, Inc. | 24 | $28,436 |
| Alcon | 3 | $114 |
| NEW World Medical,inc. | 2 | $56 |
| Thea Pharma Inc. | 1 | $22 |
| Sight Sciences, Inc. | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rocklatan$28,143
- Rhopressa$7,975
- Travoprost Intraocular Implant - iDose$7,202
- DURYSTA$6,925
- XEN$3,615
- iStent Trabecular Micro-Bypass Stent System$2,000
- iStent inject Trabecular Micro-Bypass Stent System$1,470
- ALPHAGAN P$488
- iStent inject W$180
- iStent infinite Trabecular Micro-Bypass System Model iS3$148
- iS3-iStent infiniteTrabecular Micro-Bypass System Model iS3$148
How this compares
$358,632 in reported general payments places this provider in the 95th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 310 | $162,494 |
| RhopressaNetarsudil Mesylate | 289 | $144,693 |
| RocklatanNetarsudil Mesylat/Latanoprost | 194 | $106,700 |
| VyzultaLatanoprostene Bunod | 132 | $67,792 |
| CombiganBrimonidine Tartrate/Timolol | 150 | $61,715 |
| Alphagan PBrimonidine Tartrate | 111 | $50,878 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 155 | $46,993 |
| Brimonidine Tartrate | 735 | $41,416 |
| RestasisCyclosporine | 21 | $25,345 |
| Travoprost | 108 | $23,628 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 1,106 | $20,973 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 106 | $20,847 |
| Brinzolamide | 87 | $18,578 |
| Latanoprost | 1,350 | $18,506 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 83 | $18,311 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P, Restasis | $39,076 | $300,432592 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $28,436 | $251,393483 claims |
| AlconSimbrinza, Azopt | $114 | $60,424178 claims |
| Thea Pharma Inc.Iyuzeh | $22 | $7,63615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 920 ophthalmology providers in Pennsylvania.
Other ophthalmology in Philadelphia
- Julia HallerPhiladelphia$1.5M
- Beeran MeghparaPhiladelphia$496K
- Mark BlecherPhiladelphia$357K
- Anton KolomeyerPhiladelphia$355K
- Durga BorkarPhiladelphia$150K
- Rachel NiknamPhiladelphia$142K
- Joseph MarkoffPhiladelphia$130K
- Leslie KatzPhiladelphia$105K
- Zeba SyedPhiladelphia$99K
- Cesar BricenoPhiladelphia$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.